Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Velzatinib versus imatinib in previously untreated metastatic or unresectable GIST
jRCT2011260011Phase 3Recruiting
- Sponsor
- GSK
- Start
- Aug 2026
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in gastrointestinal stromal tumor (GIST) comparing Velzatinib arm with Imatinib arm (2 arms). Primary endpoint: Progression-Free Survival. Started Aug 2026; status: recruiting.
02
Drugs
IDRX-42imatinib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on jRCT2011260011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011260011.